Leo Cancer Care, a medical technology company transforming the future of radiation therapy through upright patient positioning, has successfully closed an oversubscribed $65 million Series D funding round. The investment will help the company accelerate global commercialization, expand manufacturing capabilities, and continue developing its next-generation cancer imaging and treatment platform.
The funding round was led by Silicon Valley-based Yu Galaxy, with participation from new investors including Eventide Asset Management. Existing investors also continued their support, reinforcing confidence in Leo Cancer Care’s mission to redefine how cancer treatments are delivered.
Funding to Accelerate Next-Generation Cancer Treatment Platforms
The fresh capital will support the expansion of Leo Cancer Care’s integrated upright technology ecosystem, which includes proton therapy, photon therapy, and advanced imaging solutions. Unlike traditional systems that require patients to lie down during imaging and radiation treatment, Leo Cancer Care has designed its technology around the body’s natural upright position.
The company believes this approach can improve the overall treatment experience by aligning medical technology around patients rather than requiring patients to adapt to large treatment machines.
Research into upright positioning suggests potential benefits in anatomical consistency and organ stability compared with conventional supine (lying-down) approaches, creating new possibilities for more patient-focused cancer care.
Stanford Medicine Achieves Major Milestone With Upright Proton Therapy
Leo Cancer Care’s Marie® upright proton therapy system recently reached a historic achievement when Stanford Medicine delivered the world’s first compact upright proton therapy treatment on June 4, 2026. The treatment involved a seven-year-old patient with a complex brain tumor.
Traditional proton therapy facilities often require large rotating gantry systems. Leo Cancer Care’s approach keeps the radiation beam fixed while carefully rotating the seated patient, significantly reducing infrastructure requirements.
According to the company, this design enables proton therapy treatment rooms to be approximately five times smaller than conventional gantry-based systems, potentially allowing hospitals to introduce advanced proton therapy within existing radiotherapy spaces.
Expanding Access to Advanced Cancer Care Globally
Several leading healthcare institutions have started adopting Leo Cancer Care’s upright treatment approach. Organizations including Stanford Medicine, Dana-Farber Cancer Institute, and McLaren Health Care are bringing the company’s technology into their cancer treatment programs.
The adoption spans major academic medical centers as well as regional healthcare networks, supporting Leo Cancer Care’s goal of making advanced cancer therapies available to more patients worldwide.
Along with the Series D financing, Leo Cancer Care has also entered into a strategic partnership with a major international healthcare organization. Further details of the collaboration are expected to be revealed separately.
Leadership Comments on the Funding
Stephen Towe, CEO and Co-Founder of Leo Cancer Care, said the company’s journey has expanded beyond improving radiation therapy into creating a broader transformation in cancer care delivery.
“What began as a vision to improve radiation therapy has evolved into something much broader,” said Towe. He added that the company aims to redesign treatment around the patient rather than the machine, enabling advanced care to reach more communities without reducing treatment capabilities.
PR Yu, founder of Yu Galaxy and long-time investor in Leo Cancer Care, said the company’s upright radiotherapy and radiology innovations have the potential to expand access to cancer treatment worldwide.
The Future of Upright Cancer Therapy
With the new $65 million investment, Leo Cancer Care plans to increase deployment of its upright cancer care technology while continuing clinical development across proton therapy, photon therapy, and imaging.
As healthcare systems worldwide look for more accessible and efficient cancer treatment solutions, Leo Cancer Care’s patient-centered platform represents a growing shift toward compact, innovative, and scalable oncology technologies.